Client Services

At AXIS, we understand better than most, the unique challenges faced by pharmaceutical companies trying to secure access to the Irish Market for new medicines. Ireland has its own specific processes and requirements that must be followed if you are to be successful in your reimbursement submissions. Our team of experts has over 30 years’ experience in securing reimbursement from the Health Service Executive for many new healthcare technologies from clients across the globe and an in-depth understanding of the routes to both the public and private healthcare market in Ireland.

The multidisciplinary team at AXIS is comprised of exceptionally talented individuals with backgrounds in science, medical writing, health economics, mathematics and statistics, allowing us to prepare compelling Health Technology Assessments (HTA’s) that are specifically tailored for appraisal by the Irish HTA agency, the National Centre for Pharmacoeconomics (NCPE). We ensure a clear, accurate, comprehensive and compelling written narrative is prepared to accompany cost-effectiveness and budget impact models that are correctly recalibrated for Ireland using local Irish data. Having prepared over 75 submissions for the NCPE to date, we know what makes for a good quality submission and how to avoid lengthy delays arising with poorly prepared ones.

High quality evidence-based data is essential, whether for an actual HTA submission to the NCPE or for use in Price Negotiations meeting with the Irish authorities at the HSE’s Corporate Pharmaceutical Unit. Our team has extensive experience in searching for key data which we source through comprehensive systematic literature reviews, pragmatic reviews, conducting in-depth interviews with Clinicians in Ireland as well as hosting Advisory Boards and Delphi Panels.

We understand the importance of evidence in Payer decision making and a particular focus at AXIS is to ensure applications made for medicines to treat Rare diseases accurately reflect the care pathway in Ireland.